Pleiotropic effects of vitamin D in chronic kidney disease

Clinica Chimica Acta

Volumn 453, Issue , 2016, Pages 1-12

  Liu, Wen Chih ^a,b   Wu, Chia Chao ^c   Hung, Yao Min ^d,e   Liao, Min Tser ^c,f   Shyu, Jia Fwu ^g   Lin, Yuh Feng ^a,h   Lu, Kuo Cheng ⁱ   Yeh, Kun Chieh ^f  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CARDINAL TIEN HOSPITAL   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^g NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^h SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

ⁱ FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

Chronic kidney disease; Combination vitamin D therapy; Extraskeletal health; Skeletal quality; Vitamin D

Indexed keywords

24 HYDROXYLASE; 25 HYDROXYVITAMIN D; ANTIANEMIC AGENT; CALCITRIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; OXYGENASE; PARATHYROID HORMONE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ALBUMINURIA; ANEMIA; BLOOD PRESSURE REGULATION; BONE DISEASE; BONE FAT CONNECTION; BONE QUALITY; BONE REMODELING; BONE TURNOVER; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIETARY REFERENCE INTAKE; DRUG MECHANISM; END STAGE RENAL DISEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME ACTIVITY; FRACTURE; HORMONE ACTION; HUMAN; HYPERCALCEMIA; IMMUNE RESPONSE; LIPID METABOLISM; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; ANIMAL; BONE; CHRONIC KIDNEY FAILURE; DRUG EFFECTS; METABOLISM; RISK;

ANIMALS; BONE AND BONES; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK; VITAMIN D;

EID: 84949543490     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.11.029     Document Type: Review

References (152)

1. Galassi A., Bellasi A., Auricchio S., Papagni S., Cozzolino M. Which vitamin D in CKD-MBD? The time of burning questions. Biomed. Res. Int. 2013, 2013:864012.
2. Zhu N., Wang J., Gu L., Wang L., Yuan W. Vitamin D supplements in chronic kidney disease. Ren. Fail. 2015, 1-8.
3. Holick M.F. Vitamin D: a D-Lightful health perspective. Nutr. Rev. 2008, 66:S182-S194.
4. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357:266-281.
5. Bhan I., Hewison M., Thadhani R. Dietary vitamin D intake in advanced CKD/ESRD. Semin. Dial. 2010, 23:407-410.
6. Nykjaer A., Dragun D., Walther D., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96:507-515.
7. Holick M.F. Resurrection of vitamin D deficiency and rickets. J. Clin. Invest. 2006, 116:2062-2072.
8. DeLuca H.F. Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr. 2004, 80:1689S-1696S.
9. Dusso A.S., Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int. 2011, 79:715-729.
10. Boros S., Bindels R.J., Hoenderop J.G. Active Ca(2+) reabsorption in the connecting tubule. Pflugers Arch. Eur. J. Physiol. 2009, 458:99-109.
11. Deluca H.F. History of the discovery of vitamin D and its active metabolites. BoneKEy Rep. 2014, 3:479.
12. Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D. Am. J. Physiol. Ren. Physiol. 2005, 289:F8-28.
13. Andress D.L. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006, 69:33-43.
14. Liu P.T., Stenger S., Li H., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
15. Hewison M., Burke F., Evans K.N., et al. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J. Steroid Biochem. Mol. Biol. 2007, 103:316-321.
16. Rojas-Rivera J., De La Piedra C., Ramos A., Ortiz A., Egido J. The expanding spectrum of biological actions of vitamin D. Nephrol. Dial. Transplant. 2010, 25:2850-2865.
17. Nigwekar S.U., Bhan I., Thadhani R. Ergocalciferol and cholecalciferol in CKD. Am. J. Kidney Dis. 2012, 60:139-156.
18. Hossein-nezhad A., Holick M.F. Vitamin D for health: a global perspective. Mayo Clin. Proc. 2013, 88:720-755.
19. Gunta S.S., Thadhani R.I., Mak R.H. The effect of vitamin D status on risk factors for cardiovascular disease. Nat. Rev. Nephrol. 2013, 9:337-347.
20. Kalantar-Zadeh K., Kovesdy C.P. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4:1529-1539.
21. Holick M.F. Vitamin D: extraskeletal health. Rheum. Dis. Clin. N. Am. 2012, 38:141-160.
22. Harms L.R., Burne T.H., Eyles D.W., McGrath J.J. Vitamin D and the brain. Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25:657-669.
23. Girgis C.M., Clifton-Bligh R.J., Turner N., Lau S.L., Gunton J.E. Effects of vitamin D in skeletal muscle: falls, strength, athletic performance and insulin sensitivity. Clin. Endocrinol. 2014, 80:169-181.
24. Norman P.E., Powell J.T. Vitamin D and cardiovascular disease. Circ. Res. 2014, 114:379-393.
25. Li Y.C. Vitamin D regulation of the renin-angiotensin system. J. Cell. Biochem. 2003, 88:327-331.
26. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence?. Br. J. Nutr. 2003, 89:552-572.
27. Martineau A.R., Honecker F.U., Wilkinson R.J., Griffiths C.J. Vitamin D in the treatment of pulmonary tuberculosis. J. Steroid Biochem. Mol. Biol. 2007, 103:793-798.
28. Brown A.J., Dusso A., Slatopolsky E. Vitamin D. Am. J. Physiol. 1999, 277:F157-F175.
29. Aranda A., Pascual A. Nuclear hormone receptors and gene expression. Physiol. Rev. 2001, 81:1269-1304.
30. Burke L.J., Baniahmad A. Co-repressors 2000. FASEB J. 2000, 14:1876-1888.
31. Carlberg C., Campbell M.J. Vitamin D receptor signaling mechanisms: integrated actions of a well-defined transcription factor. Steroids 2013, 78:127-136.
32. Chronic Kidney Disease Prognosis C, Matsushita K., van der Velde M., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073-2081.
33. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004, 351:1296-1305.
34. Nigwekar S.U., Tamez H., Thadhani R.I. Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). BoneKEy Rep. 2014, 3:498.
35. Ravani P., Malberti F., Tripepi G., et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009, 75:88-95.
36. Wolf M., Shah A., Gutierrez O., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007, 72:1004-1013.
37. Zehnder D., Landray M.J., Wheeler D.C., et al. Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study. Nephron Clin. Pract. 2007, 107:c109-c116.
38. Christakos S., Ajibade D.V., Dhawan P., Fechner A.J., Mady L.J. Vitamin D: metabolism. Endocrinol. Metab. Clin. N. Am. 2010, 39:243-253. (table of contents).
39. Zierold C., Darwish H.M., DeLuca H.F. Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:900-902.
40. Tourigny A., Charbonneau F., Xing P., et al. CYP24A1 exacerbated activity during diabetes contributes to kidney tubular apoptosis via caspase-3 increased expression and activation. PLoS One 2012, 7.
41. Larsson T., Nisbeth U., Ljunggren O., Juppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003, 64:2272-2279.
42. Prie D., Friedlander G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clin. J. Am. Soc. Nephrol. 2010, 5:1717-1722.
43. Massart A., Debelle F.D., Racape J., et al. Biochemical parameters after cholecalciferol repletion in hemodialysis: results from the VitaDial randomized trial. Am. J. Kidney Dis. 2014, 64:696-705.
44. Ding C., Gao D., Wilding J., Trayhurn P., Bing C. Vitamin D signalling in adipose tissue. Br. J. Nutr. 2012, 108:1915-1923.
45. Ishimura E., Nishizawa Y., Inaba M., et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int. 1999, 55:1019-1027.
46. van Leeuwen J.P., Pols H.A., Schilte J.P., Visser T.J., Birkenhager J.C. Modulation by epidermal growth factor of the basal 1,25(OH)2D3 receptor level and the heterologous up-regulation of the 1,25(OH)2D3 receptor in clonal osteoblast-like cells. Calcif. Tissue Int. 1991, 49:35-42.
47. Reinhardt T.A., Horst R.L. Parathyroid hormone down-regulates 1,25-dihydroxyvitamin D receptors (VDR) and VDR messenger ribonucleic acid in vitro and blocks homologous up-regulation of VDR in vivo. Endocrinology 1990, 127:942-948.
48. Godschalk M., Levy J.R., Downs R.W. Glucocorticoids decrease vitamin D receptor number and gene expression in human osteosarcoma cells. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 1992, 7:21-27.
49. van Driel M., Koedam M., Buurman C.J., et al. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J. 2006, 20:2417-2419.
50. Haussler M.R., Haussler C.A., Whitfield G.K., et al. The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "Fountain of Youth" to mediate healthful aging. J. Steroid Biochem. Mol. Biol. 2010, 121:88-97.
51. Fretz J.A., Zella L.A., Kim S., Shevde N.K., Pike J.W. 1,25-Dihydroxyvitamin D3 induces expression of the Wnt signaling co-regulator LRP5 via regulatory elements located significantly downstream of the gene's transcriptional start site. J. Steroid Biochem. Mol. Biol. 2007, 103:440-445.
52. Paredes R., Arriagada G., Cruzat F., et al. The Runx2 transcription factor plays a key role in the 1alpha,25-dihydroxy Vitamin D3-dependent upregulation of the rat osteocalcin (OC) gene expression in osteoblastic cells. J. Steroid Biochem. Mol. Biol. 2004, 89-90:269-271.
53. Shen Q., Christakos S. The vitamin D receptor, Runx2, and the Notch signaling pathway cooperate in the transcriptional regulation of osteopontin. J. Biol. Chem. 2005, 280:40589-40598.
54. van Driel M., Koedam M., Buurman C.J., et al. Evidence that both 1alpha,25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization. J. Cell. Biochem. 2006, 99:922-935.
55. Zhou Y.S., Liu Y.S., Tan J.G. Is 1, 25-dihydroxyvitamin D3 an ideal substitute for dexamethasone for inducing osteogenic differentiation of human adipose tissue-derived stromal cells in vitro?. Chin. Med. J. 2006, 119:1278-1286.
56. Zhou S., Glowacki J., Kim S.W., et al. Clinical characteristics influence in vitro action of 1,25-dihydroxyvitamin D(3) in human marrow stromal cells. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2012, 27:1992-2000.
57. Pols H.A., Birkenhager J.C., Schilte J.P., Visser T.J. Evidence that the self-induced metabolism of 1,25-dihydroxyvitamin D-3 limits the homologous up-regulation of its receptor in rat osteosarcoma cells. Biochim. Biophys. Acta 1988, 970:122-129.
58. Staal A., van den Bemd G.J., Birkenhager J.C., Pols H.A., van Leeuwen J.P. Consequences of vitamin D receptor regulation for the 1,25-dihydroxyvitamin D3-induced 24-hydroxylase activity in osteoblast-like cells: initiation of the C24-oxidation pathway. Bone 1997, 20:237-243.
59. Takeda S., Yoshizawa T., Nagai Y., et al. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. Endocrinology 1999, 140:1005-1008.
60. Helvig C.F., Cuerrier D., Hosfield C.M., et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int. 2010, 78:463-472.
61. Suda T., Takahashi F., Takahashi N. Bone effects of vitamin D - discrepancies between in vivo and in vitro studies. Arch. Biochem. Biophys. 2012, 523:22-29.
62. National Kidney F K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003, 42:S1-201.
63. Brown A.J. Therapeutic uses of vitamin D analogues. Am. J. Kidney Dis. 2001, 38:S3-S19.
64. Holick M.F. Vitamin D for health and in chronic kidney disease. Semin. Dial. 2005, 18:266-275.
65. Shroff R., Wan M., Gullett A., et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin. J. Am. Soc. Nephrol. 2012, 7:216-223.
66. Kidney disease: improving global outcomes CKDMBDWG: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 2009, S1-130.
67. Coen G., Taccone Gallucci M., Bonucci E., et al. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone. Miner. Electrolyte Metab. 1983, 9:19-27.
68. Mazzaferro S., Goldsmith D., Larsson T.E., Massy Z.A., Cozzolino M. Vitamin D metabolites and/or analogs: which D for which patient?. Curr. Vasc. Pharmacol. 2014, 12:339-349.
69. Dawson-Hughes B., Mithal A., Bonjour J.P., et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int. 2010, 21:1151-1154.
70. Tangpricha V., Wasse H. Vitamin D therapy in kidney disease: more vitamin D is necessary. Am. J. Kidney Dis. 2014, 64:667-669.
71. Miller P.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
72. Miller P.D. Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am. J. Kidney Dis. 2014, 64:290-304.
73. Anderson P.H., Lam N.N., Turner A.G., et al. The pleiotropic effects of vitamin D in bone. J. Steroid Biochem. Mol. Biol. 2013, 136:190-194.
74. Glendenning P., Inderjeeth C.A. Controversy and consensus regarding vitamin D: recent methodological changes and the risks and benefits of vitamin D supplementation. Crit. Rev. Clin. Lab. Sci. 2015, 1-16.
75. Busse B., Bale H.A., Zimmermann E.A., et al. Vitamin D deficiency induces early signs of aging in human bone, increasing the risk of fracture. Sci. Transl. Med. 2013, 5:193ra88.
76. Theodoratou E., Tzoulaki I., Zgaga L., Ioannidis J.P. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014, 348:g2035.
77. Bolland M.J., Grey A., Gamble G.D., Reid I.R. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol. 2014, 2:307-320.
78. Tang B.M., Eslick G.D., Nowson C., Smith C., Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50years and older: a meta-analysis. Lancet 2007, 370:657-666.
79. Challoumas D. Vitamin D supplementation and lipid profile: what does the best available evidence show?. Atherosclerosis 2014, 235:130-139.
80. Bouillon R., Carmeliet G., Lieben L., et al. Vitamin D and energy homeostasis: of mice and men. Nat. Rev. Endocrinol. 2014, 10:79-87.
81. Takada I., Kouzmenko A.P., Kato S. Molecular switching of osteoblastogenesis versus adipogenesis: implications for targeted therapies. Expert Opin. Ther. Targets 2009, 13:593-603.
82. Muruganandan S., Roman A.A., Sinal C.J. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell. Mol. Life Sci. 2009, 66:236-253.
83. Wu X.B., Li Y., Schneider A., et al. Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. J. Clin. Invest. 2003, 112:924-934.
84. Kajkenova O., Lecka-Czernik B., Gubrij I., et al. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 1997, 12:1772-1779.
85. Sawant A., Chanda D., Isayeva T., et al. Noggin is novel inducer of mesenchymal stem cell adipogenesis: implications for bone health and obesity. J. Biol. Chem. 2012, 287:12241-12249.
86. Bennett C.N., Ross S.E., Longo K.A., et al. Regulation of Wnt signaling during adipogenesis. J. Biol. Chem. 2002, 277:30998-31004.
87. Gimble J.M., Zvonic S., Floyd Z.E., Kassem M., Nuttall M.E. Playing with bone and fat. J. Cell. Biochem. 2006, 98:251-266.
88. Day T.F., Guo X., Garrett-Beal L., Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell 2005, 8:739-750.
89. Kang S., Bennett C.N., Gerin I., et al. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2007, 282:14515-14524.
90. Andrade A.C., Nilsson O., Barnes K.M., Baron J. Wnt gene expression in the post-natal growth plate: regulation with chondrocyte differentiation. Bone 2007, 40:1361-1369.
91. Kunadian V., Ford G.A., Bawamia B., Qiu W., Manson J.E. Vitamin D deficiency and coronary artery disease: a review of the evidence. Am. Heart J. 2014, 167:283-291.
92. Krause R., Buhring M., Hopfenmuller W., Holick M.F., Sharma A.M. Ultraviolet B and blood pressure. Lancet 1998, 352:709-710.
93. Li Y.C., Kong J., Wei M., et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
94. Nasri H., Behradmanesh S., Ahmadi A., Rafieian-Kopaei M. Impact of oral vitamin D (cholecalciferol) replacement therapy on blood pressure in type 2 diabetes patients; a randomized, double-blind, placebo controlled clinical trial. J. Nephropathol. 2014, 3:29-33.
95. Peterson C.A., Heffernan M.E. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J. Inflamm. 2008, 5:10.
96. Liu W.C., Zheng C.M., Lu C.L., et al. Vitamin D and immune function in chronic kidney disease. Clin. Chim. Acta Int. J. Clin. Chem. 2015, 450:135-144.
97. Koeffler H.P., Amatruda T., Ikekawa N., Kobayashi Y., DeLuca H.F. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. Cancer Res. 1984, 44:5624-5628.
98. Hewison M. Vitamin D and innate and adaptive immunity. Vitam. Horm. 2011, 86:23-62.
99. Antico A., Tampoia M., Tozzoli R., Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun. Rev. 2012, 12:127-136.
100. Nigwekar S.U., Thadhani R.I. Shining light on vitamin D trials in chronic kidney disease. Kidney Int. 2013, 83:198-200.
101. Harinarayan C.V. Vitamin D and diabetes mellitus. Hormones 2014, 13:163-181.
102. Gagnon C., Daly R.M., Carpentier A., et al. Effects of combined calcium and vitamin D supplementation on insulin secretion, insulin sensitivity and beta-cell function in multi-ethnic vitamin D-deficient adults at risk for type 2 diabetes: a pilot randomized, placebo-controlled trial. PLoS One 2014, 9.
103. Komaba H., Fukagawa M. Vitamin D and secreted Klotho: a long-awaited panacea for vascular calcification?. Kidney Int. 2012, 82:1248-1250.
104. Muller K., Haahr P.M., Diamant M., et al. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 1992, 4:506-512.
105. Chitalia N., Ismail T., Tooth L., et al. Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PLoS One 2014, 9.
106. Wong M.S., Leisegang M.S., Kruse C., et al. Vitamin D promotes vascular regeneration. Circulation 2014, 130:976-986.
107. Astor B.C., Matsushita K., Gansevoort R.T., et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011, 79:1331-1340.
108. Hemmelgarn B.R., Manns B.J., Lloyd A., et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010, 303:423-429.
109. de Zeeuw D., Remuzzi G., Parving H.H., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004, 65:2309-2320.
110. Gorriz J.L., Molina P., Bover J., et al. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study. Nefrologia 2013, 33:46-60.
111. Melamed M.L., Astor B., Michos E.D., et al. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J. Am. Soc. Nephrol. 2009, 20:2631-2639.
112. Holden R.M., Morton A.R., Garland J.S., et al. Vitamins K and D status in stages 3-5 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010, 5:590-597.
113. Damasiewicz M.J., Magliano D.J., Daly R.M., et al. Serum 25-hydroxyvitamin D deficiency and the 5-year incidence of CKD. Am. J. Kidney Dis. 2013, 62:58-66.
114. de Zeeuw D., Agarwal R., Amdahl M., et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
115. Fishbane S., Chittineni H., Packman M., et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am. J. Kidney Dis. 2009, 54:647-652.
116. Molina P., Gorriz J.L., Molina M.D., et al. The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: a prospective controlled study. Nephrol. Dial. Transplant. 2014, 29:97-109.
117. Pigeon C., Ilyin G., Courselaud B., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 2001, 276:7811-7819.
118. Wrighting D.M., Andrews N.C. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006, 108:3204-3209.
119. Verga Falzacappa M.V., Vujic Spasic M., Kessler R., et al. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007, 109:353-358.
120. Babitt J.L., Lin H.Y. The molecular pathogenesis of hereditary hemochromatosis. Semin. Liver Dis. 2011, 31:280-292.
121. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
122. Babitt J.L., Lin H.Y. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am. J. Kidney Dis. 2010, 55:726-741.
123. Gaweda A.E., Goldsmith L.J., Brier M.E., Aronoff G.R. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Clin. J. Am. Soc. Nephrol. 2010, 5:576-581.
124. Kalantar-Zadeh K., Lee G.H., Miller J.E., et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am. J. Kidney Dis. 2009, 53:823-834.
125. Patel N.M., Gutierrez O.M., Andress D.L., et al. Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int. 2010, 77:715-720.
126. Perlstein T.S., Pande R., Berliner N., Vanasse G.J. Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. Blood 2011, 117:2800-2806.
127. Icardi A., Paoletti E., De Nicola L., et al. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol. Dial. Transplant. 2013, 28:1672-1679.
128. Albitar S., Genin R., Fen-Chong M., et al. High-dose alfacalcidol improves anaemia in patients on haemodialysis. Nephrol. Dial. Transplant. 1997, 12:514-518.
129. Kiss Z., Ambrus C., Almasi C., et al. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis. Nephron Clin. Pract. 2011, 117:c373-c378.
130. Baeke F., Takiishi T., Korf H., Gysemans C., Mathieu C. Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 2010, 10:482-496.
131. Chow E.C., Magomedova L., Quach H.P., et al. Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol. Gastroenterology 2014, 146:1048-1059.
132. Gupta S., Pandak W.M., Hylemon P.B. LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem. Biophys. Res. Commun. 2002, 293:338-343.
133. Chiang J.Y. Bile acids: regulation of synthesis. J. Lipid Res. 2009, 50:1955-1966.
134. Jelinek D.F., Andersson S., Slaughter C.A., Russell D.W. Cloning and regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis. J. Biol. Chem. 1990, 265:8190-8197.
135. Honjo Y., Sasaki S., Kobayashi Y., Misawa H., Nakamura H. 1,25-dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor. J. Endocrinol. 2006, 188:635-643.
136. Jiang W., Miyamoto T., Kakizawa T., et al. Inhibition of LXRalpha signaling by vitamin D receptor: possible role of VDR in bile acid synthesis. Biochem. Biophys. Res. Commun. 2006, 351:176-184.
137. Singer R.F. Vitamin D in dialysis: defining deficiency and rationale for supplementation. Semin. Dial. 2013, 26:40-46.
138. Zisman A.L., Hristova M., Ho L.T., Sprague S.M. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am. J. Nephrol. 2007, 27:36-43.
139. Jean G., Terrat J.C., Vanel T., et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6months of 25-hydroxycholecalciferol treatment. Nephron Clin. Pract. 2008, 110:c58-c65.
140. Rizzoli R., Boonen S., Brandi M.L., et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr. Med. Res. Opin. 2013, 29:305-313.
141. Saliba W., Barnett O., Rennert H.S., Lavi I., Rennert G. The relationship between serum 25(OH)D and parathyroid hormone levels. Am. J. Med. 2011, 124:1165-1170.
142. Gomez-Alonso C., Naves-Diaz M.L., Fernandez-Martin J.L., et al. Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels. Kidney Int. Suppl. 2003, S44-8.
143. Ramirez J.A., Emmett M., White M.G., et al. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. 1986, 30:753-759.
144. Dusso A., Gonzalez E.A., Martin K.J. Vitamin D in chronic kidney disease. Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25:647-655.
145. Kandula P., Dobre M., Schold J.D., et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin. J. Am. Soc. Nephrol. 2011, 6:50-62.
146. Jean G., Vanel T., Terrat J.C., Chazot C. Prevention of secondary hyperparathyroidism in hemodialysis patients: the key role of native vitamin D supplementation. Hemodialysis international International Symposium on Home Hemodialysis 2010, 14:486-491.
147. Jean G., Terrat J.C., Vanel T., et al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol. Dial. Transplant. 2008, 23:3670-3676.
148. Vondracek S.F., Hoody D.W. Combination vitamin D therapy in stage 5 chronic kidney disease. Ann. Pharmacother. 2011, 45:1011-1015.
149. Aloia J.F. Clinical review: the 2011 report on dietary reference intake for vitamin D: where do we go from here?. J. Clin. Endocrinol. Metab. 2011, 96:2987-2996.
150. McNally J.D., Iliriani K., Pojsupap S., et al. Rapid normalization of vitamin D levels: a meta-analysis. Pediatrics 2015, 135:e152-e166.
151. Ozkan B., Hatun S., Bereket A. Vitamin D intoxication. Turk. J. Pediatr. 2012, 54:93-98.
152. Naik M.A., Banday K.A., Najar M.S., Reshi A.R., Bhat M.A. Vitamin D intoxication presenting as acute renal failure. Indian J. Nephrol. 2008, 18:125-126.